東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

New antimicrobials = for the present...

Fong, I. W.

FindBook

Google Book

Amazon

博客來

New antimicrobials = for the present and the future /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	New antimicrobials/ by I.W. Fong.
其他題名:	for the present and the future /
作者:	Fong, I. W.
出版者:	Cham :Springer International Publishing : : 2023.,
面頁冊數:	1 online resource (xvii, 243 p.) :ill., digital ;24 cm.
內容註:	1. Antimicrobial Resistance: A crisis in the making -- 2: New Cephalosporins: 5th and 6th generations -- 3: New β-lactam-β-lactamase inhibitor combinations -- 4: New Glycopeptides: Televancin, dalbavancin and oritavancin -- 5: A new fluoroquinolone-Delafloxacin -- 6: New Oxazolininone---Tedizolid -- 7: New Tetracyclines: Eravacycline and Omadacycline -- 8: Pleuromutilin: A new class of antibiotic: Lefamulin -- 9: New anti-tuberculous drugs: Bedaquiline, Delamanid and Pretomanid -- 10: New systemic antifungal: Isavuconazole -- 11: Newly approved anti-parasitic drugs for malaria, fascioliasis, onchocerciasis, Chagas disease and African trypanosomiasis -- 12:New antiretroviral agents for HIV infection -- 13: New Antiviral agents for cytomegalovirus diseases -- 14: New antiviral agent for influenza: Baloxavir -- 15: Direct antiviral agents for hepatitis C -- 16: Antiviral drugs for SARS-CoV-2 and COVID-19 -- 17: New promising antimicrobials in development and novel approaches for treatment of infections.
Contained By:	Springer Nature eBook
標題:	Anti-infective agents - Development. -
電子資源:	https://doi.org/10.1007/978-3-031-26078-0
ISBN:	9783031260780

New antimicrobials = for the present and the future /
Fong, I. W.

New antimicrobialsfor the present and the future /[electronic resource] :by I.W. Fong. - Cham :Springer International Publishing :2023. - 1 online resource (xvii, 243 p.) :ill., digital ;24 cm. - Emerging infectious diseases of the 21st century,2627-5872. - Emerging infectious diseases of the 21st century..

1. Antimicrobial Resistance: A crisis in the making -- 2: New Cephalosporins: 5th and 6th generations -- 3: New β-lactam-β-lactamase inhibitor combinations -- 4: New Glycopeptides: Televancin, dalbavancin and oritavancin -- 5: A new fluoroquinolone-Delafloxacin -- 6: New Oxazolininone---Tedizolid -- 7: New Tetracyclines: Eravacycline and Omadacycline -- 8: Pleuromutilin: A new class of antibiotic: Lefamulin -- 9: New anti-tuberculous drugs: Bedaquiline, Delamanid and Pretomanid -- 10: New systemic antifungal: Isavuconazole -- 11: Newly approved anti-parasitic drugs for malaria, fascioliasis, onchocerciasis, Chagas disease and African trypanosomiasis -- 12:New antiretroviral agents for HIV infection -- 13: New Antiviral agents for cytomegalovirus diseases -- 14: New antiviral agent for influenza: Baloxavir -- 15: Direct antiviral agents for hepatitis C -- 16: Antiviral drugs for SARS-CoV-2 and COVID-19 -- 17: New promising antimicrobials in development and novel approaches for treatment of infections.

This is a timely and essential companion to the recently published Antimicrobial Resistance in the 21st Century, Second Edition. Antimicrobial resistance is a major threat to global population health, with government reports projecting it could result in over 10 million deaths in the next 35 years. Development of new agents to combat this threat is one of the WHO's top priorities, but in 2017, it conceded that the current drug development pipeline was insufficient to mitigate the threat. This book discusses recent progress and bolster new agent discovery and development, by providing researchers and students who will soon enter the field with a thorough guide to the advancements made in the last decade. Coverage includes new systemic antimicrobials approved since 2010, with detailed analysis of antibiotics, antivirals, antifungals, and antiparasitics, as well as agents in development for future use. Discussion of each drug will include its chemical nature, pharmacology/pharmacokinetics, antimicrobial spectrum, dosage, adverse reactions, drug interactions, microbial resistance, indications, clinical efficacy compared to older agents, and lists of similar agents with cost comparison. This volume is designed for researchers and students of infectious disease and medical microbiology, as well as clinicians in need of a comprehensive guide to newly developed agents.

ISBN: 9783031260780

Standard No.: 10.1007/978-3-031-26078-0doiSubjects--Topical Terms:

3634585
Anti-infective agents
--Development.

LC Class. No.: RM267

Dewey Class. No.: 615.792

New antimicrobials = for the present and the future /
LDR:03444nmm a2200337 a 4500 001 2319030
003 DE-He213
005 20230525200419.0
006 m d
007 cr nn 008maaau
008 230902s2023 sz s 0 eng d
020 $a 9783031260780 $q (electronic bk.)
020 $a 9783031260773 $q (paper)
024 7 $a 10.1007/978-3-031-26078-0 $2 doi
035 $a 978-3-031-26078-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RM267
072 7 $a MMFM $2 bicssc
072 7 $a MED071000 $2 bisacsh
072 7 $a MKFM $2 thema
082 0 4 $a 615.792 $2 23
090 $a RM267 $b .F674 2023
100 1 $a Fong, I. W. $3 898715
245 1 0 $a New antimicrobials $h [electronic resource] : $b for the present and the future / $c by I.W. Fong.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2023.
300 $a 1 online resource (xvii, 243 p.) : $b ill., digital ; $c 24 cm.
490 1 $a Emerging infectious diseases of the 21st century, $x 2627-5872
505 0 $a 1. Antimicrobial Resistance: A crisis in the making -- 2: New Cephalosporins: 5th and 6th generations -- 3: New β-lactam-β-lactamase inhibitor combinations -- 4: New Glycopeptides: Televancin, dalbavancin and oritavancin -- 5: A new fluoroquinolone-Delafloxacin -- 6: New Oxazolininone---Tedizolid -- 7: New Tetracyclines: Eravacycline and Omadacycline -- 8: Pleuromutilin: A new class of antibiotic: Lefamulin -- 9: New anti-tuberculous drugs: Bedaquiline, Delamanid and Pretomanid -- 10: New systemic antifungal: Isavuconazole -- 11: Newly approved anti-parasitic drugs for malaria, fascioliasis, onchocerciasis, Chagas disease and African trypanosomiasis -- 12:New antiretroviral agents for HIV infection -- 13: New Antiviral agents for cytomegalovirus diseases -- 14: New antiviral agent for influenza: Baloxavir -- 15: Direct antiviral agents for hepatitis C -- 16: Antiviral drugs for SARS-CoV-2 and COVID-19 -- 17: New promising antimicrobials in development and novel approaches for treatment of infections.
520 $a This is a timely and essential companion to the recently published Antimicrobial Resistance in the 21st Century, Second Edition. Antimicrobial resistance is a major threat to global population health, with government reports projecting it could result in over 10 million deaths in the next 35 years. Development of new agents to combat this threat is one of the WHO's top priorities, but in 2017, it conceded that the current drug development pipeline was insufficient to mitigate the threat. This book discusses recent progress and bolster new agent discovery and development, by providing researchers and students who will soon enter the field with a thorough guide to the advancements made in the last decade. Coverage includes new systemic antimicrobials approved since 2010, with detailed analysis of antibiotics, antivirals, antifungals, and antiparasitics, as well as agents in development for future use. Discussion of each drug will include its chemical nature, pharmacology/pharmacokinetics, antimicrobial spectrum, dosage, adverse reactions, drug interactions, microbial resistance, indications, clinical efficacy compared to older agents, and lists of similar agents with cost comparison. This volume is designed for researchers and students of infectious disease and medical microbiology, as well as clinicians in need of a comprehensive guide to newly developed agents.
650 0 $a Anti-infective agents $x Development. $3 3634585
650 0 $a Drug resistance in microorganisms. $3 669099
650 1 4 $a Medical Microbiology. $3 890951
650 2 4 $a Immunology. $3 611031
650 2 4 $a Internal Medicine. $3 858559
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
830 0 $a Emerging infectious diseases of the 21st century. $3 3222067
856 4 0 $u https://doi.org/10.1007/978-3-031-26078-0
950 $a Medicine (SpringerNature-11650)